Intercept Pharma (ICPT) Receives BT Designation from the FDA

Shares of Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) are up more than 12.60% to $194 in after hours trading, as traders react to the company’s announcement that its investigational product obeticholic acid (OCA) has received “breakthrough therapy designation” from the FDA for the treatment of patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. This indication constitutes a […] View the full post at: Intercept Pharma (ICPT) Receives BT Designation from the FDA No related posts.